Pancreastatin-dependent inflammatory signaling mediates obesity-induced insulin resistance

Diabetes

Volumn 64, Issue 1, 2015, Pages 104-116

  Bandyopadhyay, Gautam K ^a,b   Lu, Minh ^a   Avolio, Ennio ^b   Siddiqui, Jawed A ^a   Gayen, Jiaur R ^c   Wollam, Joshua ^b   Vu, Christine U ^b   Chi, Nai Wen ^a,b   O'Connor, Daniel T ^a,b   Mahata, Sushil K ^a,b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; GLUCOSE 6 PHOSPHATASE; PANCREASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; CHROMOGRANIN A; CHROMOGRANIN A, MOUSE; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, MOUSE; PANCREAS HORMONE; PANCREASTATIN-52; SREBF1 PROTEIN, MOUSE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMOTAXIS; CONTROLLED STUDY; DIET INDUCED OBESITY; DOWN REGULATION; ENZYME DEFICIENCY; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PHENOTYPE; UPREGULATION; WHITE ADIPOSE TISSUE; ADIPOSE TISSUE; ANIMAL; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; GENETICS; GLUCOSE INTOLERANCE; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; OBESITY; PANNICULITIS; SIGNAL TRANSDUCTION;

ADIPOSE TISSUE; ANIMALS; CELLS, CULTURED; CHEMOTAXIS; CHROMOGRANIN A; FORKHEAD TRANSCRIPTION FACTORS; GLUCOSE INTOLERANCE; INSULIN RESISTANCE; MACROPHAGES, PERITONEAL; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; OBESITY; PANCREATIC HORMONES; PANNICULITIS; SIGNAL TRANSDUCTION; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 84920056793     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-1747     Document Type: Article

References (49)

1. Winkler H, Fischer-Colbrie R. The chromogranins A and B: The first 25 years and future perspectives. Neuroscience 1992;49:497-528
2. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med 2003;348:1134-1149
3. Montero-Hadjadje M, Vaingankar S, Elias S, Tostivint H, Mahata SK, Anouar Y. Chromogranins A and B and secretogranin II: evolutionary and functional aspects. Acta Physiol (Oxf) 2008;192:309-324
4. Bartolomucci A, Possenti R, Mahata SK, Fischer-Colbrie R, Loh YP, Salton SR. The extended granin family: structure, function, and biomedical implications. Endocr Rev 2011;32:755-797
5. Mahata SK, O'Connor DT, Mahata M, et al. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 1997;100:1623-1633
6. Mahata SK, Mahata M, Wakade AR, O'Connor DT. Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A(344-364)): identification of amino acid residues crucial for activity. Mol Endocrinol 2000;14:1525-1535
7. Wen G, Mahata SK, Cadman P, et al. Both rare and common polymorphisms contribute functional variation at CHGA, a regulator of catecholamine physiology. Am J Hum Genet 2004;74:197-207
8. Mahata SK, Mahata M, Fung MM, O'Connor DT. Catestatin: A multifunctional peptide from chromogranin A. Regul Pept 2010;162:33-43
9. Tatemoto K, Efendic S, Mutt V, Makk G, Feistner GJ, Barchas JD. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature 1986; 324:476-478
10. O'Connor DT, Cadman PE, Smiley C, et al. Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism. J Clin Endocrinol Metab 2005;90:5414-5425
11. Gayen JR, Saberi M, Schenk S, et al. A novel pathway of insulin sensitivity in chromogranin A null mice: A crucial role for pancreastatin in glucose homeostasis. J Biol Chem 2009;284:28498-28509
12. Sánchez-Margalet V, González-Yanes C, Najib S, Santos-Alvarez J. Metabolic effects and mechanism of action of the chromogranin A-derived peptide pancreastatin. Regul Pept 2010;161:8-14
13. Mahapatra NR, O'Connor DT, Vaingankar SM, et al. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest 2005;115:1942-1952
14. Gayen JR, Gu Y, O'Connor DT, Mahata SK. Global disturbances in autonomic function yield cardiovascular instability and hypertension in the chromogranin a null mouse. Endocrinology 2009;150:5027-5035
15. Dev NB, Gayen JR, O'Connor DT, Mahata SK. Chromogranin a and the autonomic system: decomposition of heart rate variability and rescue by its catestatin fragment. Endocrinology 2010;151:2760-2768
16. Gayen JR, Zhang K, RamachandraRao SP, et al. Role of reactive oxygen species in hyperadrenergic hypertension: biochemical, physiological, and pharmacological evidence from targeted ablation of the chromogranin a (Chga) gene. Circ Cardiovasc Genet 2010;3:414-425
17. Bandyopadhyay GK, Vu CU, Gentile S, et al. Catestatin (chromogranin A(352- 372)) and novel effects on mobilization of fat from adipose tissue through regulation of adrenergic and leptin signaling. J Biol Chem 2012;287:23141-23151
18. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-Alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91
19. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: Tssociations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972-978
20. Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-47
21. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-334
22. Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab 2012;15:635-645
23. Pini M, Rhodes DH, Castellanos KJ, Cabay RJ, Grady EF, Fantuzzi G. Rosiglitazone improves survival and hastens recovery from pancreatic inflammation in obese mice. PLoS ONE 2012;7:e40944
24. Zhao D, McCully BH, Brooks VL. Rosiglitazone improves insulin sensitivity and baroreflex gain in rats with diet-induced obesity. J Pharmacol Exp Ther 2012;343:206-213
25. Foryst-Ludwig A, Hartge M, Clemenz M, et al. PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice. Cardiovasc Diabetol 2010;9:64
26. Kim JK. Hyperinsulinemic-euglycemic clamp to assess insulin sensitivity in vivo. Methods Mol Biol 2009;560:221-238
27. Zhang X, Goncalves R, Mosser DM. The isolation and characterization of murine macrophages. In Current Protocols in Immunology. Coligan JE, Ed. Hoboken, NJ, John Wiley & Sons, 2008, p. 1-14
28. Li P, Spann NJ, Kaikkonen MU, et al. NCoR repression of LXRs restricts macrophage biosynthesis of insulin-sensitizing omega 3 fatty acids. Cell 2013; 155:200-214
29. González-Yanes C, Sánchez-Margalet V. Pancreastatin, a chromogranin A-derived peptide, inhibits leptin and enhances UCP-2 expression in isolated rat adipocytes. Cell Mol Life Sci 2003;60:2749-2756
30. O'Neill LA, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 2013;493:346-355
31. Bijland S, Mancini SJ, Salt IP. Role of AMP-Activated protein kinase in adipose tissue metabolism and inflammation. Clin Sci (Lond) 2013;124:491-507
32. Galic S, Fullerton MD, Schertzer JD, et al. Hematopoietic AMPK b1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity. J Clin Invest 2011;121:4903-4915
33. Sag D, Carling D, Stout RD, Suttles J. Adenosine 59-monophosphateactivated protein kinase promotes macrophage polarization to an antiinflammatory functional phenotype. J Immunol 2008;181:8633-8641
34. Rajaram MV, Ganesan LP, Parsa KV, Butchar JP, Gunn JS, Tridandapani S. Akt/Protein kinase B modulates macrophage inflammatory response to Francisella infection and confers a survival advantage in mice. J Immunol 2006; 177:6317-6324
35. de Oliveira AC, Candelario-Jalil E, Langbein J, et al. Pharmacological inhibition of Akt and downstream pathways modulates the expression of COX-2 and mPGES-1 in activated microglia. J Neuroinflammation 2012;9:2
36. Hoogendijk AJ, Pinhanços SS, van der Poll T, Wieland CW. AMP-Activated protein kinase activation by 5-Aminoimidazole-4-carbox-Amide-1-b-D-ribofuranoside (AICAR) reduces lipoteichoic acid-induced lung inflammation. J Biol Chem 2013;288: 7047-7052
37. Zhao X, Zmijewski JW, Lorne E, et al. Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury. Am J Physiol Lung Cell Mol Physiol 2008;295:L497-L504
38. Huang JB, Ding Y, Huang DS, et al. Inhibition of the PI3K/AKT pathway reduces tumor necrosis factor-Alpha production in the cellular response to wear particles in vitro. Artif Organs 2013;37:298-307
39. Smith MV, Lee MJ, Islam AS, et al. Inhibition of the PI3K-Akt signaling pathway reduces tumor necrosis factor-Alpha production in response to titanium particles in vitro. J Bone Joint Surg Am 2007;89:1019-1027
40. Kidd LB, Schabbauer GA, Luyendyk JP, et al. Insulin activation of the phosphatidylinositol 3-kinase/protein kinase B (Akt) pathway reduces lipopolysaccharide-induced inflammation in mice. J Pharmacol Exp Ther 2008; 326:348-353
41. Makki K, Froguel P, Wolowczuk I. Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines. ISRN Inflamm 2013;2013:139239
42. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112:1821-1830
43. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010;72:219-246
44. Bouloumié A, Casteilla L, Lafontan M. Adipose tissue lymphocytes and macrophages in obesity and insulin resistance: makers or markers, and which comes first? Arterioscler Thromb Vasc Biol 2008;28:1211-1213
45. Biswas N, Friese RS, Gayen JR, Bandyopadhyay G, Mahata SK, O'Connor DT. Discovery of a novel target for the dysglycemic chromogranin A fragment pancreastatin: interaction with the chaperone GRP78 to influence metabolism. PLoS ONE 2014;9:e84132
46. Yamamoto T, Shimano H, Nakagawa Y, et al. SREBP-1 interacts with hepatocyte nuclear factor-4 alpha and interferes with PGC-1 recruitment to suppress hepatic gluconeogenic genes. J Biol Chem 2004;279:12027-12035
47. Chakravarty K, Hanson RW. Insulin regulation of phosphoenolpyruvate carboxykinase-c gene transcription: The role of sterol regulatory element-binding protein 1c. Nutr Rev 2007;65:S47-S56
48. Nakae J, Kitamura T, Kitamura Y, Biggs WH 3rd, Arden KC, Accili D. The forkhead transcription factor Foxo1 regulates adipocyte differentiation. Dev Cell 2003;4:119-129
49. Fan W, Imamura T, Sonoda N, et al. FOXO1 transrepresses peroxisome proliferator-Activated receptor gamma transactivation, coordinating an insulininduced feed-forward response in adipocytes. J Biol Chem 2009;284:12188-12197